Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT06959017

Diffrence in Thromboprofilaksis in Elderly Ostoepenic Hip Fractures According to Mobility Status by Genetic Analysis

Hip fracture is a common and severe disease in elderly patients. The question of the study is whether elderly patients with severe osteopenia have significantly lower levels of the collagen-binding protein Hsp47 than relatively mobile patients due to advanced immobility before the fracture, and whether they participants have a similar risk of VTE to the normal population despite having had a hip fracture and surgery.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Key information

Conditions

Hip Fracture of Intertrochanteric Type Bone Diseases Bone Diseases, Metabolic Cardiovascular Diseases Congenital Abnormalities Congenital, Hereditary, and Neonatal Diseases and Abnormalities Embolism and Thrombosis Femoral Fractures Fractures, Bone Genetic Diseases, Inborn Hereditary Sensory and Autonomic Neuropathies Heredodegenerative Disorders, Nervous System Hip Fractures Hip Injuries Leg Injuries Metabolic Diseases Musculoskeletal Diseases Nervous System Diseases Nervous System Malformations Neurodegenerative Diseases Neuromuscular Diseases Nutritional and Metabolic Diseases Osteopenia Peripheral Nervous System Diseases Polyneuropathies Thromboembolic Event Thromboembolism Thrombosis Embolism Vascular Diseases Wounds and Injuries

Age range

65 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Prof Dr emil Tascıoglu City Hospital

Istanbul, Şişli, 34384, Turkey (Türkiye)

About this study

In this study, the investigators aimed to prospectively measure the Hsp 47 gene expression levels in patients scheduled for surgery due to intertrochanteric femur fracture and healthy volunteers in the same age group and compare the results with the literature.

Also the complications prior or after surgery will be compared.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • >65 years of age
  • Interthrocanteric femur fracture AO Type 31A1, 31A2, 31A3
  • Patients treated proksimal femoral nail
  • Minor trauma
  • Fracture mobility score 1,2,3,4,5
  • Inial thrombocytes count 150.000-450.000 /µL

Exclusion criteria

  • Body mass index >40
  • Fracture mobility score 6 (unknown type)
  • stage 4 chronic kidney disease
  • Patients with rheumatological diseases
  • Patients at serious risk of VTE(Venous thromboembolism) (according to the International Society on Thrombosis and Hemostasis, categorization of venous thromboembolism) :
  • Active Hematologic Cancer
  • Antiphospholipid syndrome
  • History of recurrent thrombosis (DVT)
  • Paroxysmal nocturnal hemoglobinuria

Treatment and study plan

gene expression analysis

Genetic

Each subject analysed for SERPİNH1 and ROCK1 gene exppression

Primary outcomes

  1. HSP 47

    Time frame: Gene expression analysis will be performed once samples are collected from all participants.

    HSP 47 (SERPİNH1, ROCK1) gene expression analysis

Secondary outcomes

  1. Thromboembolie

    Time frame: from fracture occur up to one year

    Thromboembolic events

Sponsors and collaborators

Lead sponsor

Saglik Bilimleri Universitesi

Other

Registry information

Official study title

Is Thromboprotection Preserved in Elderly Ostopenic Patients Who Are Severly Immobilized Before Hip Fracture?

Acronym: HSP 47

Important dates

Study start
2024
Primary completion
2025
Study completion
2025
First posted
May 6, 2025
Registry last updated
Jun 5, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.